Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study will gather data on potential biomarkers in the treatment of advanced renal cell
carcinoma (kidney cancer) and investigate their use as indicators of disease response. The
results could eventually enable doctors to match levels of therapy to levels of biomarker on
an individual basis and to increase the chance of disease response in patients. This study
will also test a new paradigm in the treatment approach of advanced kidney cancer by using
the drug everolimus in a neo-adjuvant setting, with the overarching goal of decreasing cancer
recurrence rates and improving patient outcomes and survival.